Skip to main content

Table 2 Clinical characteristics of patients with systemic lupus erythematosus #

From: Antagonist-mediated down-regulation of toll-like receptors increases the prevalence of human papillomavirus infection in systemic lupus erythematosus

  Group 1
(HPV-positive)
(SLE patients = 15)
Group 2
(HPV-negative)
(SLE patients = 31)
Clinical features   
   SLE duration, mean ± S.D.(range), year 18 ± 8 (6 to 36) 13 ± 6 (5 to 28)
   SLICC, median (IQR) 1 (0 to 2) 0 (0 to 1)
   SLEDAI score, median (IQR) 2 (0 to 6) 2 (0 to 4)
Serological features   
   Serum complement C3, median (IQR), g/l 0.9 (0.7 to 1.1) 0.8 (0.6 to 1.0)
   Serum complement C4, median (IQR), g/l 0.2 (0.1 to 0.3) 0.2 (0.1 to 0.3)
   Elevated anti-dsDNA (> 100 IU/ml) 6 (40) 13 (42)
   Anti-dsDNA titer, median (IQR), IU/ml 308 (210 to 591) 331 (93 to 572)
Major organ involvement ever   
   0 0 (0) 3 (10)
   1 1 (7) 9 (29)
   ≥ 2 14 (93) 19 (61)
   Neuropsychiatric 3 (20) 10 (32)
   Nephritis 12 (80) 17 (55)
   Serositis 6 (40) 7 (23)
   Hematologic 15 (100) 24 (77)
Immunosuppressive therapy ever 15 (100) 29 (94)
   Prednisolone 14 (93) 24 (77)
   Hydroxychloroquine 12 (80) 15 (48)
   Azathioprine 9 (60) 16 (52)
   Cyclophosphamide (oral or IV) 2 (13) 5 (16)
   Cyclosporin A 2 (13) 7 (23)
   Mycophenolate mofetil 3 (20) 5 (16)
  1. # Values are the number (percentage) unless otherwise indicated. * Refers to atypical squamous cells of undetermined significance or squamous intraepithelial lesions. Anti-dsDNA, anti-double stranded DNA;
  2. IQR, interquartile range; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index; SLICC, systemic lupus international collaborating clinics/Americal College of Rheumatology damage index. Group 1, SLE with positive HPV DNA; Group 2, SLE with negative HPV DNA; P <0.05 comparing between SLE patients with and without HPV infection.